Across TCGA pan-cancer cohorts, TRAF3IP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAF3IP3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher TRAF3IP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAF3IP3 expression acts as an unfavorable survival marker.
SCLC, ACC, and UCEC are the cancer types where TRAF3IP3 Mutation most reproducibly stratifies survival.